• Idera Pharmaceuticals Inc., of Cambridge, Mass., said it will delay its planned Phase II study of Toll-like receptor 9 agonist IMO-2125 based on preliminary data from a 26-week nonclinical toxicology study in rodents showing instances of atypical lymphocytic proliferation. The company expects data from the nonhuman primate study and additional histology data from the rodent study during the second half of this year. The planned Phase II study is expected to test IMO-2125 plus ribavirin in treatment-naïve genotype 1 hepatitis C patients.